SLC18A2 and Huntington disease: Therapies currently approved by the FDA for the treatment of HD include vesicular monoamine transporter 2 inhibitors [tetrabenazine (Xenazine®) and deutetrabenazine (Austedo®)] that reduce chorea, a symptom that affects ∼90% of HD patients, and antipsychotics and other pharmacological agents that help manage cognitive and behavioral manifestations of HD.